PARP Inhibitor Active in Non-BRCA Ovarian Ca (CME/CE)

posted on Aug 21 by MedPage Today OB/Gyn in the Uncategorized category (MedPage Today) -- Advanced ovarian cancer, regardless of BRCA mutations, responded to treatment with PARP inhibitor olaparib, data from an open-label trial showed.